Phase i trial of CYT997, a novel cytotoxic and vascular-disrupting agent

British Journal of Cancer

Volumn 103, Issue 5, 2010, Pages 597-606

  Lickliter, J D ^a,b,c   Francesconi, A B ^a   Smith, G ^d   Burge, M ^a   Coulthard, A ^e   Rose, S ^e   Griffin, M ^e   Milne, R ^f   McCarron, J ^b   Yeadon, T ^b   Wilks, A ^d   Cubitt, A ^a   Wyld, D K ^a   Vasey, P A ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

^d Cytopia Ltd   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

CYT997; DCE MRI; pharmacokinetics; phase I clinical trial; vascular disrupting agents

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYT997; CYTOKERATIN 18; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOXIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL COUNT; ENDOTHELIAL CELLS; FEMALE; HUMANS; KERATIN-18; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRIDINES; PYRIMIDINES; VON WILLEBRAND FACTOR;

EID: 77955978648     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605841     Document Type: Article

References (25)

1. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24: 1491-1498
2. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6: 835-845
3. Burns CJ, Fantino E, Phillips ID, Su S, Harte MF, Bukczynska PE, Frazzetto M, Joffe M, Kruszelnicki I, Wang B, Wang Y, Wilson N, Dilley RJ, Wan SS, Charman SA, Shackleford DM, Fida R, Malcontenti-Wilson C, Wilks AF (2009a) CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Mol Cancer Ther 8: 3036-3045
4. Burns CJ, Harte MF, Bu X, Fantino E, Joffe M, Sikanyika H, Su S, Tranberg CE, Wilson N, Charman SA, Shackleford DM, Wilks AF (2009b) Discovery of CYT997: a structurally novel orally active microtubule targeting agent. Bioorg Med Chem Lett 19: 4639-4642
5. Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40: 403-439
6. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC (2004) Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10: 96-100
7. Cytopia Research Pty Ltd (2009) CYT997 Investigator's Brochure 7th edn, Richmond, Victoria, Australia
8. De Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, De Jong S, De Vries EG, Dive C, Gietema JA (2008) Clinical evaluation of M30 and M65ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10: 1041-1048
9. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408-3416
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247
11. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18
12. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831-2842
13. Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96: 1159-1165
14. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD (2005) Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 105: 526-532
15. Li KL, Zhu XP, Waterton J, Jackson A (2000) Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors. J Magn Reson Imaging 12: 347-357
16. McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB (2006) 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 12: 1776-1784
17. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99: 2006-2012
18. Moch H, Oberholzer M, Dalquen P, Wegmann W, Gudat F (1993) Diagnostic tools for differentiating between pleural mesothelioma and lung adeno-carcinoma in paraffin embedded tissue. Part I: immunohistochemical findings. Virchows Arch A Pathol Anat Histopathol 423: 19-27
19. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21: 2815-2822
20. Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601
21. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA (2007) Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia 9: 128-135
22. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147
23. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438
24. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, Hill SA (2008) Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 81(Spec No. 1): S12-S20
25. Watson Y, Cheung S, Roberts C, Buonaccorsi GA, Davies KE, Jackson A, Ton C, Broughton L, Power F, Jayson GC, Lang Z, Mullamitha S, Beckman R, Parker GJ (2006) Prognostic power of DCE-MRI heterogeneity analysis in patients with advanced solid tumours. Proc Intl Soc Mag Reson Med 14: 755